Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
UDxXvcNZRcBzyYjC